Gyre Therapeutics Inc., a biotechnology company specializing in organ fibrosis, has announced the commencement of an underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase additional shares at the public offering price, excluding underwriting discounts and commissions. The offering's completion and terms are dependent on market conditions, with no guarantees provided. The proceeds from this offering will be used to advance a Phase 2 clinical trial for F351 in the United States, focusing on MASH-associated liver fibrosis, as well as for research, development, manufacturing, and general corporate purposes. Jefferies is leading the offering as the book-running manager, with H.C. Wainwright & Co. acting as co-manager.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。